SecBot SecBot
Biotech Drug Report Generated Jul 14, 2026

SNDX-4321

SNDX·Syndax Pharmaceuticals Inc
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical (IND-enabling)
Time to market
Unknown, preclinical; IND filing targeted by end of 2026, Phase 1 in 2027. Commercialization would be years away if clinical trials succeed.
Why 2/10
SNDX-4321 is a preclinical-stage asset with no hard, dated binary catalyst in the next ~12 months. The next milestone is an IND filing targeted by end of 2026, followed by a Phase 1 start in 2027, neither is a price-moving binary for a company that already has two FDA-approved, commercial-stage products (Revuforj, Niktimvo). As a small part of a larger pipeline, impactScore is low.
Actionable Insight NEUTRAL

SNDX-4321 is too early-stage to drive meaningful stock movement. Investors should focus on Syndax's nearer-term catalysts: upcoming Phase 2 data for axatilimab in IPF (4Q26) and cGVHD (4Q26), and the commercial ramp of approved products Revuforj and Niktimvo (~$200M combined annualizing as of 1Q26).

Price Chart

Loading chart...

Executive Summary

SNDX-4321 is a preclinical-stage, mutant-selective allosteric EGFR inhibitor for non-small cell lung cancer (NSCLC), unveiled by Syndax Pharmaceuticals at its July 2026 R&D event. The molecule was externally developed and Syndax holds exclusive worldwide rights. An IND submission is planned by end of 2026 with a Phase 1 trial start in 2027. At this early stage, SNDX-4321 is a minor part of Syndax's pipeline, which already includes two FDA-approved products (Revuforj and Niktimvo) and later-stage programs. No near-term binary catalysts are attached to this asset.

How It Works

SNDX-4321 is a precision drug designed to target specific mutated forms of the EGFR protein found in some non-small cell lung cancers. It is "allosteric," meaning it binds to a different part of the protein than standard EGFR inhibitors, and "mutant-selective," meaning it targets cancer-causing mutations while potentially sparing normal EGFR activity, which may reduce side effects common to existing EGFR drugs.

Trial Status

Preclinical stage. Syndax plans to submit an IND by end of 2026 and initiate a Phase 1 trial in EGFR-mutated NSCLC in 2027. The molecule was externally developed and Syndax holds an exclusive worldwide license.

The Two-Sided Case

▲ Bull Case3
Mutant-selective allosteric EGFR inhibitors represent a potentially differentiated approach vs. existing EGFR TKIs; if successful, SNDX-4321 could address NSCLC patients with high unmet need.
Syndax has experience bringing cancer drugs to market (Revuforj approved Dec 2024, Niktimvo approved Aug 2024), providing a commercial infrastructure that could support future launches.
The molecule was disclosed at a dedicated R&D event, suggesting management sees meaningful potential, and the exclusive worldwide license structure aligns incentives.
▼ Bear Case4
SNDX-4321 is preclinical, no human efficacy or safety data exist. The vast majority of preclinical oncology candidates fail before or during Phase 1.
The EGFR inhibitor space is intensely competitive, with approved drugs from AstraZeneca (osimertinib/Tagrisso), Johnson & Johnson, and others already established as standard of care.
IND filing >12 months away means no near-term catalyst; this is a long-duration, high-risk pipeline option that provides optionality at best.
As an externally licensed asset, Syndax likely faces financial obligations (milestones, royalties) that could reduce the economic upside.

Upcoming Catalysts

  • IND filing targeted by end of 2026
  • Phase 1 trial initiation in EGFR-mutated NSCLC expected in 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Syndax Pharmaceuticals Inc 8-K SNDX ·Originating report

Sources · 5

Hover a chip for the title
1 biospace.com2 rallies.ai3 minichart.com.sg4 markets.businessinsider.com5 sec.gov